autologous anti-mesothelin car-il-7-ccl19-expressing t-lymphocytes tak-103
Generic: Autologous Anti-mesothelin CAR-IL-7-CCL19-expressing T-lymphocytes TAK-103
autologous anti-mesothelin car-il-7-ccl19-expressing t-lymphocytes tak-103: 1 clinical trial tracked.
autologous anti-mesothelin car-il-7-ccl19-expressing t-lymphocytes tak-103 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous anti-mesothelin car-il-7-ccl19-expressing t-lymphocytes tak-103, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors
Primary endpoint: Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Interventionalopen2 enrolledStarted 2022-01Completion 2025-023 sites · JapanTakeda